Showing results (1031-1040 of 6,501) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|May 1, 1993
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2F Arienti, F Belli, L Rivoltini, et al.Cancer Immunology, Immunotherapy : CII|June 1, 1993
Application of the direct beta counter Matrix 96 for cytotoxic assays: simultaneous processing and reading of 96 wells using a 51Cr-retention assayG G Hillman, N Roessler, R S Fulbright, et al.Cancer Immunology, Immunotherapy : CII|June 1, 1993
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsP A Ruffini, L Rivoltini, A Silvani, et al.Cancer Immunology, Immunotherapy : CII|November 1, 1995
Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitroK Pryor, P Stricker, P Russell, et al.Cancer Immunology, Immunotherapy : CII|July 1, 1996
Mucin-1-related T cell infiltration in colorectal carcinomaW M Mulder, M J Stukart, E de Windt, et al.Cancer Immunology, Immunotherapy : CII|May 1, 1996
Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigensA F Kirkin, P thor Straten, J ZeuthenCancer Immunology, Immunotherapy : CII|May 1, 1996
Effects of ifosfamide on immunocompetent effector cellsG Multhoff, C Botzler, A Allenbacher, et al.Cancer Immunology, Immunotherapy : CII|October 13, 1998
Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic miceE Nagai, T Ogawa, T Kielian, et al.Cancer Immunology, Immunotherapy : CII|October 13, 1998
In vitro propagated dendritic cells from patients with human-papilloma virus-associated preneoplastic lesions of the uterine cervix: use of Flt3 ligandP Hubert, R Greimers, E Franzen-Detrooz, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1997
Distinct biological activities of recombinant forms of human interleukin-2 in vivoA B Lentsch, K Nakagawa, H Yoshidome, et al.Pageof 651